Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary in Vitro Immunization with Peptide-Pulsed Dendritic Cells

Journal of Immunology

Volumn 158, Issue 4, 1997, Pages 1796-1802

  Tsai, Van ^a   Southwood, Scott ^a   Sidney, John ^a   Sakaguchi, Kazuyasu ^b   Kawakami, Yutaka ^b   Appella, Ettore ^b   Sette, Alessandro ^a   Celis, Esteban ^a  

^a CYTEL CORPORATION   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; MELANOMA SPECIFIC ANTIGENS; MELANOMA-SPECIFIC ANTIGENS; PEPTIDE; TUMOR ANTIGEN; TUMOR PROTEIN;

ARTICLE; CELL LINE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROTEIN BINDING;

ANTIGENS, NEOPLASM; CELL LINE, TRANSFORMED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDES; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031568658     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Nabholz, M., and H. R. MacDonald. 1983. Cytolytic T lymphocytes. Annu. Rev. Immunol. 1:273.
2. Melief, C. J., and W. M. Kast. 1992. Lessons from T cell responses to virus induced tumours for cancer eradication in general. Cancer Surv. 13:81.
3. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318.
4. Rammensee, H. G., K. Falk, and O. Rotzschke. 1993. MHC molecules as peptide receptors. Curr. Opin. Immunol. 5:35.
5. Germain, R. N., and D. H. Margulies. 1993. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11:403.
6. Berke, G. 1994. The binding and lysis of target cells by cytotoxic T lymphocytes: molecular and cellular aspects. Annu. Rev. Immunol. 12:735.
7. Lanzuvecchia, A. 1993. Identifying strategies for immune intervention. Science 260:937.
8. Sercarz, E, E., P. V. Lehmann, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1993. Dominance and crypticity of T cell antiganic determinants. Annu. Rev. Immunol. 11:729.
9. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
10. Kubo, R. T., A. Sette, H. M. Grey, E. Appella, K. Sakaguchi, N. Z. Zhu, D. Arnott, N. Sherman, J. Shabanowitz, H. Michel, W. M. Bodnar, T. A. Davis, and D. F. Hunt. 1994. Definition of specific peptide motifs for four major HLA-A alleles. J. Immunol. 152:3913.
11. Ruppert, J., J. Sidney, E. Celis, R. T. Kubo, H. M. Grey, and A. Sette. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929.
12. Kast, W. M., R. M. Brandt, J. Sidney, J. W. Drijfhout, R. T. Kubo, H. M. Grey, C. J. Melief, and A. Sette. 1994. Role of HLA-A montifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152:3904.
13. + CTL response to infleunza hemagglutinin epitope reflects limited T cell availability. J. Immunol. 157:505.
14. Jameson, S. C., and M. J. Bevan. 1992. Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a Kb-restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs. Eur. J. Immunol. 22:2663.
15. Wipke, B. T., S. C. Jameson, M. J. Bevan, and E. G. Pamer. 1993. Variable binding affinities of listeriolysin O peptides for the H-2Kd class I molecule. Eur. J. Immunol. 23:2005.
16. Chen, W., S. Khilko, J. Fecondo, D. H. Margulies, and J. McCluskey. 1994. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J. Exp. Med. 180:1471.
17. Oldstone, M. A. 1991. Molecular anatomy of viral persistence. J. Virol. 65:6381.
18. Li, W.-F., M.-D. Fan, C.-B. Pan, and M.-Z. Lai. 1992. T cell epitope selection: dominance may be determined by both affinity for major histocompatibility complex and stoichiometry of epitope. Eur. J. Immunol. 22:943.
19. b-binding peptides from influenza virus: effect of non-anchor residues on stability and immunodominance. Mol. Immunol. 32:623.
20. Oukka, M., N. Riche, and K. Kosmatopoulos. 1994. A nonimmundominant nucleoprotein-derived peptide is presented by influenza A virus-infected H-2b cells. J. Immunol. 152:4843.
21. Houbiers, J. G., H. W. Nijman, S. H. van der Burg, J. W. Drijfhout, P. Kenemans, C. J. van de Velde, A. Brand, F. Momburg, W. M. Kast, and C. J. Melief. 1993. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23:2072.
22. Wentworth, P. A., E. Celis, C. Crimi, S. Stitely, L. Hale, V. Tsai, H. M. Serra, M. F. del Guercio, B. Livingston, D. Alazard, J. Fikes, R. T. Kubo, H. M. Grey, R. W. Chesnut, F. V. Chisari, and A. Sette. 1995. In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. Mol. Immunol. 32:603.
23. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, and R. W. Chesnut. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytologic T lymphocyte response in humans. J. Clin. Invest. 95:341.
24. Marchand, M., P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, J.-L. Canon, C. Laurent, J.-M. Naeyaert, R. Plagne, R. Daraemaeker, A. Knuth, E. Jager, F. Brasseur, J. Herman, P. G. Coulie, and T. Boon. 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63:883.
25. Jäeger, E., H. B. H. P. Romero, M. Ringhoffer, M. Arand, J. Karbach, C. Ilsemann, M. Hagedorn, and A. Knuth. 1996. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66:162.
26. Mukherji, B., N. G. Chakraborty, S. Yamasaki, T. Okino, H. Yamase, J. R. Sporn, S. K. Kurtzman, M. T. Ergin, J. Ozols, J. Meehan, and F. Mauri. 1995. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA 92:8078.
27. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Apulia, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
28. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognation multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
29. Bakker, A. B., M. W. Schreurs, G. Tafazzul, B. A. J. de, Y. Kawakami, G. J. Adema, and C. G. Figdor. 1995. Identification of a novel peptide derived from the melanocyte-specific-gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer 62:97.
30. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Singluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
31. Sette, A., J. Sidney, M. F. del Guercio, S. Southwood, J. Ruppert, C. Dahlberg, H. M. Grey, and R. T. Kubo. 1994. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol. Immunol. 31:813.
32. Celis, E., V. Tsai, C. Crimi, R. DeMars, P. A. Wentworth, R. W. Chesnut, H. M. Grey, A. Sette, and H. M. Serra. 1994. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91:2105.
33. Tsai, V., G. S. Firestein, W. Arend, and N. J. Zvaifler. 1992. Cytokine-induced differentiation of cultured non-adherent macrophages. Cell. Immunol. 144:203.
34. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179:1109.
35. van, d. B. P., J. Bastin, T. Gajewski, P. G. Coulie, P. Boel, S. C. De, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24:3038.
36. Gaeliardi, M. C., G. D. Petrillo, S. Salemi, L. Boffa, M. G. Longobardi, P. Dellabona, G. Casorati, N. Tanigaki, R. Harris, A. Lanzavecchia, and V. Barnaba. 1995. Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro. Int. Immunol. 7:1741.
37. Bakker, A. B. H., G. Marland, A. J. d. Boer, R. J. F. Huijbens, E. H. J. Danen, G. J. Adema, and C. G. Figdor. 1995. Generation of anti-melanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55:5330.
38. Plebanski, M., C. E. M. Allsopp, H. Reyburn, and H. A. V. S. 1994. Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. Eur. J. Immunol. 25:1783.
39. + helper T cells. J. Exp. Med. 171:1315.
40. + CTLs from naive precursors. J. Immunol. 153:996.
41. Nair, S., J. S. Babu, R. G. Dunham, P. Kanda, R. L. Burke, and B. T. Rouse. 1993. Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J. Virol. 67:4062.
42. Kos, F. J., and A. Müllbacher. 1992. Induction of primary-antiviral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin-7. Eur. J. Immunol. 22:2183.
43. Chen, W.-F., and A. Zlotnik. 1991. IL-10: a novel cytotoxic T cell differentiation factor. J. Immunol. 147:528.
44. Yang, G., K. E. Hellstrom, M. T. Mizuno, and L. Chen. 1995. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J. Immunol. 155:3897.
45. Celis, E., A. Sette, and H. M. Grey. 1995. Epitope selection and development of peptide based vaccines to treat cancer. Semin. Cancer Biol. 6:329.
46. Cibotti, R., J. M. Kanellopoulos, J.-P. Cabaniols, O. Halle-Panenko, K. Kosmatopoulos, E. Sercarz, and P. Kourilsky. 1992. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. USA 89:416.
47. Lanzavecehia, A. 1995. How can cryptic epitopes trigger autoimmumty. J. Exp. Med. 181:1945.
48. Fairchild, P. J., and D. C. Wraith. 1996. Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol. Today 17:80.
49. Roseberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159.